What kind of person lets a black mamba sink its fangs into their arm-on purpose-and then comes back for more? For Tim Friede, a Wisconsin native and self-taught venom expert, this wasn’t some kind of death-defying stunt but rather a two-decade-long scientific experiment that has now become the foundation for one of the most promising advances in antivenom technology in over a century.
Since 2001, Friede has endured over 200 bites and more than 850 injections of venom from some of the world’s deadliest snakes, including king cobras, coastal taipans, tiger snakes, and common kraits. His method was quite deliberate: milking venom from his snakes, then diluting it and giving himself increasing doses to challenge his immune system into producing potent antitoxin antibodies. Eventually, he tested his immunity by direct bites a practice that several times nearly killed him, as when he went into a four-day coma after a twin cobra strike. It always burns and it’s always, always painful, Friede said. Was it a mistake? Yes. Was it stupid? Yes.
The scientific payoff came when Jacob Glanville, the chief executive of Centivax and an expert in computational immunology, realized that Friede’s immune system was a living archive of broadly neutralizing antibodies. Traditional antivenom is produced by immunizing horses or sheep against venom and harvesting their antibodies. Though effective, such sera derived from animals are species-specific, can provoke severe allergic reactions, and usually demand exact identification of the snake before treatment. Friede’s blood was something different: human antibodies matured in vivo against an enormous diversity of venom toxins.
From Friede’s memory B cells, two antibodies of remarkable breadth were isolated. LNX-D09 targets long-chain three-finger α-neurotoxins, which bind to nicotinic acetylcholine receptors and cause rapid paralysis. Structural studies revealed that the CDR-H3 loop of LNX-D09 mimics the receptor’s “loop C” to occlude the toxin active site. SNX-B03 targets short-chain neurotoxins, binding via a similar receptor-mimicking mechanism. These toxins are among the most lethal components in elapid venoms, which dominate in species such as mambas, cobras, and kraits.
To counter other venom components, the authors added varespladib, a small-molecule inhibitor of PLA2, an enzyme causing membrane damage, neurotoxicity, and systemic effects in many elapid species. Thus, the three component cocktail of LNX-D09, SNX-B03, and varespladib was evaluated against a World Health Organization panel of 19 medically critical elapid species. In preclinical mouse models, it provided complete protection against 13 species, including black mamba, king cobra, tiger snake, inland taipan, and common krait, and partial protection against six others such as Russian cobra and western green mamba.
Thus, the engineering approach was deeply rooted in evolutionary toxin conservation. The antibodies achieved a level of cross-species neutralization unparalleled by conventional antivenoms by targeting “toxicity cores” that are structurally invariant across species. At the same time, the modularity of this approach implies that future cocktails could be expanded with additional antibodies to cover other toxin families such as metalloproteinases and procoagulants expressed by vipers, which cause hemorrhage and tissue destruction.
This has global implications: snakebite envenoming kills 81,000 to 138,000 people annually and leaves up to 400,000 with permanent disabilities, with the highest burden in South Asia and sub-Saharan Africa. Many rural victims die because antivenom is unavailable, unaffordable, or mismatched to the snake species. A universal, human-derived antivenom would obviate the need for species identification, permit stockpiling of a single product, and reduce manufacturing fragmentation that currently constrains supply.
Centivax’s next step will be field testing in Australia, where the only venomous snakes are elapids, and where dog bites are common. Success there could lead to human clinical trials. A parallel cocktail already is in the works for viperid snakes, with a two-formula solution in view. “We’re turning the crank now, setting up reagents to go through this iterative process of saying what’s the minimum sufficient cocktail to provide broad protection against venom from the viperids.” says Peter Kwong of Columbia University.
Friede’s self-immunization was dangerous and is strictly disallowed by scientists. But his “once-in-history” immune profile has opened up a new frontier in toxinology. The combination of structural immunology, recombinant antibody engineering, and small-molecule synergy represents a shift from century-old serum-based treatments toward precision-designed, scalable biotherapeutics that could transform snakebite care for millions worldwide.
